EZH2 and neoplasm: We show here that the SAM-competitive EZH2 inhibitor UNC1999 exhibits low micromolar cytotoxicity in vitro on a diverse collection of BTIC lines, synergizes with Dexamethasone (DEX) and suppresses tumor growth in vivo in combination with DEX.